Sunday 18 October 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022. In the quarter to June 2026, revenue fell 57.1%, EPS grew 99.5% and free cash flow grew 167.7%, each against the same quarter a year earlier.
2.68
0.48
−15.19%
Follow IBO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
0.00 | — | — | 0.00 |
Altman Z-Score |
0.34 | — | — | — |
P/S ratio |
194.72 | — | — | 0.00 |
P/FCF ratio |
0.00 | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(2.38) | — | — | (0.09) |
P/Operating CF |
161.29 | — | — | (69.76) |
P/B ratio |
1.03 | — | — | 1.02 |
Price to Tangible BV |
0.00 | — | — | 0.00 |
EV/Sales |
291.89 | — | — | 0.00 |
EV/EBITDA |
0.00 | — | — | 0.00 |
EV/Operating CF |
(12.66) | — | — | (13.63) |
EV/FCF |
(12.54) | — | — | (13.50) |
Quick Ratio |
0.01 | 0.20 | 0.01 | 0.00 |
Current Ratio |
0.35 | 0.25 | 0.03 | 0.01 |
Net Debt/EBITDA |
0.00 | 0.79 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.16 | 0.12 | 0.66 | 0.32 |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | (0.25) |
Interest Coverage |
(5.40) | (27.00) | (9.07) | (7.37) |
| (104.15%) | (139.68%) | (14.25%) | 0.00% | |
| (62.81%) | (76.11%) | (9.52%) | 0.00% | |
ROIC |
(17.21%) | (343.08%) | (8.91%) | (6.51%) |
Return on Tangible Assets |
1,576.30% | 337.54% | 34.64% | 69.16% |
Average Days of Receivables |
57.03 | — | 0.00 | 0.00 |
Research and Development Expense of Revenue |
1,062.50% | 0.00% | 0.00% | 2,452.00% |
Selling, General and Administrative Expense of Revenue |
2,803.13% | 0.00% | 0.00% | 650.00% |
Intangible Assets out of Total Assets |
0.98 | 0.88 | 0.99 | 0.97 |
Share Based Compensation of Revenue |
40.63% | 0.00% | — | 0.00% |
Graham Net Nets |
(0.09) | — | — | (0.65) |
Graham Number |
0.00 | — | — | 0.00 |
Earnings Yield |
(75.36%) | — | — | (8.69%) |
Free Cash Flow Yield |
(11.95%) | — | — | (7.41%) |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.01 |
Operating CF per Share |
(0.76) | (3.35) | (0.60) | (0.40) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.05) |
Free Cash Flow per Share |
(0.76) | (3.35) | (0.60) | (0.45) |
Cash per Share |
0.00 | 2.35 | 0.00 | 0.00 |
Shareholders Equity per Share |
6.23 | 8.49 | 5.92 | 5.85 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.23 | 8.49 | 5.92 | 5.85 |
Free Cash Flow |
(1.89) | (2.85) | (2.87) | (2.52) |
Working Capital |
(0.75) | (7.34) | (12.80) | (10.47) |
Capital Expenditures |
— | — | (0.02) | (0.28) |
Net Current Asset Value |
(1.44) | (10.60) | (16.04) | (13.71) |
EV/EBIT |
0.00 | — | — | 0.00 |
Capex to Sales |
0.00 | — | 0.00 | 5.52 |
Price to Operating Income |
0.00 | — | — | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.00 | 1,541.88 | 3.90 | 4.03 |
Cash ROIC |
(12.15%) | (30.90%) | (10.15%) | (7.71%) |
Accounts Receivable Turnover |
0.48 | — | — | 0.00 |
Accounts Payable Turnover |
1.28 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | — | — | — |
Average Days of Payables |
298.71 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
54.23 | — | — | — |
Average Receivables |
0.07 | — | — | — |
Average Payables |
0.33 | 0.57 | 0.69 | — |
Average Assets |
18.85 | 32.46 | 45.57 | — |
Average Common Equity |
11.37 | 17.69 | 30.44 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026